Article
Targeting of CXCR4 by the naturally occurring CXCR4 antagonist EPI-X 4 in Waldenström’s Macroglobulinemia
2020-10-19
Abstract excerpt
CXCR4 expression and downstream signaling have been identified as key factors in malignant hematopoiesis. Thus, up to 40% of all patients with Waldenström’s Macroglobulinemia (WM) carry an activating mutation of CXCR4 that leads to a more aggressive clinical course and inferior outcome upon treatment with the Bruton’s tyrosine kinase inhibitor ibrutinib. Nevertheless, little is known about physiological mechanisms...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- d9e9cc93-5851-5f5f-a7e3-371defc92999
- DOI
- 10.1101/2020.10.19.344812
